Hydroxyurea for sickle cell anemia [8]

New England Journal of Medicine

Volumn 359, Issue 1, 2008, Pages 98-99

  Naina, Harris V K ^a   Harris, Samar ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT; HEMOGLOBIN A; HEMOGLOBIN F;

ALOPECIA; BONE MARROW SUPPRESSION; CANCER RISK; DRUG RESEARCH; HUMAN; HYPERPIGMENTATION; LEG ULCER; LETTER; NAIL PIGMENTATION; NEOPLASM; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SICKLE CELL ANEMIA; THORAX DISEASE; XEROSIS; HEALTH CARE DELIVERY; INTERPERSONAL COMMUNICATION; NOTE; PATIENT COMPLIANCE; BLOOD;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; DISCLOSURE; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYUREA; PATIENT COMPLIANCE; FETAL HEMOGLOBIN; HEMOGLOBIN A;

EID: 46449125664     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080902     Document Type: Letter

References (2)

1. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008;358:1362-9.
2. Schecter AN, Ajioka RS, Kushner JP. Hemoglobin and heme biosynthesis. In: Young NS, Gerson SL, High KA, eds. Clinical hematology. Philadelphia: Elsevier, 2006:16-33.